Reproductive Health Matters
Volume 16, Issue 32 , Pages 97-103 , November 2008

Human papillomavirus vaccination in the United Kingdom: what about boys?

References 

  1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907
  2. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infectious Diseases. 2006;6(1):21–31
  3. National Health Service. Q&A on HPV vaccines. At: < www.immunisation.nhs.uk/files/HPV_Q&A.pdf>. Accessed 1 June 2008
  4. Kmietowicz Z. Choice of cancer vaccine is branded a missed opportunity by charities. BMJ. 2008;336:1456–1457
  5. FPA. FPA statement on new cervical cancer vaccine. 18 June 2008. At: < www.fpa.org.uk/news/press/current/detail.cfm?contentID=1005>. Accessed 28 September 2008
  6. Giuliano AR. Human papillomavirus vaccination in males. Gynecologic Oncology. 2007;107:S24–S26
  7. Newall AT, Beutels P, Wood JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases. 2007;7(4):289–296
  8. Public Health and Wellbeing Directorate. Implementation of Immunisation Programme: Human Papilloma Virus (HPV) Vaccine – Project Update including the Catch Up Campaign. 6 February 2008. At: < www.sehd.scot.nhs.uk/mels/CEL2008_05.pdf>. Accessed 1 June 2008
  9. Kim JJ. Human papillomavirus vaccination in the UK. BMJ. 2008;337:a842
  10. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769
  11. NHS. Q+A on HPV vaccines. 2007. At: < www.immunisation.nhs.uk/files/HPV_Q&A.pdf>. Accessed 4 October 2008
  12. Dunne EF, Nielson CM, Stone KM, et al. Prevalence of HPV infection among men: a systematic review of the literature. Journal of Infectious Diseases. 2006;194:1044–1057
  13. Bleeker MCG, Hogewoning CJ, Berkhof J, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clinical Infectious Diseases. 2005;41:612–620
  14. WHO/ICO Information Centre on HPV and Cervical Cancer. Human Papillomavirus and Cervical Cancer. 2007. At: < www.who.int/hpvcentre/statistics/dynamic/ico/country_pdf/GBR.pdf?CFID=278048&CFTOKEN=18959369>. Accessed 4 October 2008
  15. Jit M, Vyse A, Borrow R, et al. Prevalence of human papillomavirus antibodies in young female subjects in England. British Journal of Cancer. 2007;97:989–991
  16. Sanofi Pasteur MSD Limited. Gardasil. 26 February 2008. At: < www.emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=19016>. Accessed 1 June 2008
  17. ClinicalTrials.gov. An Investigational Study of Gardasil (V501) in Reducing the Incidence of Anogenital Warts in Young Men. At: < www.clinicaltrials.gov/ct2/show/NCT00090285?term=Gardasil+young+men&rank=1>. Accessed 1 June 2008
  18. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Paediatrics. 2006;118:2135–2145
  19. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases. 2007;13(1):28–41
  20. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. Journal of Infectious Diseases. 2005;191:S97–S106
  21. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology. 2002;13(6):631–639
  22. Anon . Should HPV vaccines be mandatory for all adolescents?. Lancet. 2006;368:1212
  23. Böttiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine. 1997;15(14):1538–1544
  24. Vyse AJ, Gay NJ, White JM, et al. Evolution of surveillance of measles, mumps and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiologic Reviews. 2002;24:125–136
  25. Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. Journal of National Cancer Institute. 1996;88:1060–1067
  26. Svare EI, Kjaer SK, Worm AM, et al. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sexually Transmitted Infections. 2002;78:215–218
  27. Johnson AM, Mercer CH, Erens B, et al. Sexual behaviour in Britain: partnerships, practices and HIV risk behaviours. Lancet. 2001;358:1835–1842
  28. Health Protection Agency. Genital warts statistics. 26 February 2008. At: < www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733781837>. Accessed 16 May 2008
  29. Nielson CN, Flores RB, Harris M, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiololgy Biomarkers and Prevention. 2007;16:1107–1114
  30. Campion MJ, Singer A, Clarkson PK, et al. Increased risk of cervical neoplasia in consorts of men with penile condylomata acuminate. Lancet. 1985;1:943–946
  31. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine. 2006;24(S1):23–28
  32. Joint Committee on Vaccination and Immunisation. Minutes of the HPV Sub-group meeting, Tuesday, 23 May 2006. 6 March 2008. At: < http://advisorybodies.doh.gov.uk/jcvi/mins-hpv-230506.htm>. Accessed 1 June 2008
  33. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24(S3):11–25
  34. Frisch M, Fenger C, van den Brule AJ, et al. Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomavirus. Cancer Research. 1999;59:753–757
  35. Palefsky JM, Gillison ML, Strickler HD. Chapter 16: HPV vaccines in immunocompromised women and men. Vaccine 2006;24:S3/140–46.
  36. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. New England Journal of Medicine. 2007;356:1944–1956
  37. Gillison ML. Human papillomavirus-associated head and neck cancer in a distinct epidemiologic, clinical, and molecular entity. Seminars in Oncology. 2004;31(6):744–754
  38. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. New England Journal of Medicine. 2001;344:1125–1131
  39. Cancer Research UK. UK Oral Cancer Statistics. August 2007. At: < http://info.cancerresearchuk.org/cancerstats/types/oral?a=5441>. Accessed 16 May 2008
  40. Cancer Research UK. Definite risks for mouth and oropharyngeal cancer. July 2008. At: < http://www.cancerhelp.org.uk/help/default.asp?page=13053>. Accessed 4 October 2008
  41. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833–1839
  42. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection in the anal canal in HIV-positive and HIV-negative homosexual men. Journal of Infectious Diseases. 1998;177:361–367
  43. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. Journal of National Cancer Institute. 2000;92:1500–1510
  44. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection in anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Annals of Internal Medicine. 2003;183:453–459
  45. Cancer Research UK. Risks and causes of anal cancer. March 2008. At: < http://www.cancerhelp.org.uk/help/default.asp?page=20808>. Accessed 4 October 2008
  46. Roberts M. Gay men seek “female cancer” jab. BBC News. 23 February 2007. At: < http://news.bbc.co.uk/1/hi/health/6342105.stm>. Accessed 1 December 2007
  47. Udesky L. Push to mandate HPV vaccine triggers backlash in USA. Lancet. 2007;369(9566):979–980
  48. Boynton P. HPV Vaccine - will be introduced in the UK for girls only. 26 October 2007. At: < www.drpetra.co.uk/blog/?p=573>. Accessed 1 December 2007
  49. Ndong I, Finger WR. Male responsibility for reproductive health. Network. 1998;18(3):4–6

PII: S0968-8080(08)32413-6

doi: 10.1016/S0968-8080(08)32413-6

Reproductive Health Matters
Volume 16, Issue 32 , Pages 97-103 , November 2008

Article Tools

* Image Usage & Resolution